Use of gabapentinoid medications among US adults with cancer, 2005–2015
Gabapentinoid use for long-term cancer pain control may be problematic, given unclear mechanisms of action and increased concerns for physical dependence. The purpose of this report is to examine trends of gabapentinoid use among US adults with cancer from 2005 to 2015.
We conducted a serial, cross-sectional study using data from the Medical Expenditure Panel Survey (MEPS). We performed multiple logistic regression to examine the annual percentages of gabapentinoid users, which were adjusted for age, sex, and US region of residence. The amount of gabapentinoid prescriptions filled in 2015 was also estimated.
The adjusted percentage of gabapentinoid users in 2015 was 5.60% (3.79%, 7.41%), 2.39 times greater than the percentage in 2005 (p < .001). By 2015, the number of gabapentinoid prescriptions had grown to approximately 3.52 million (2.40 million, 4.65 million).
We observed greater than a twofold increase in the trend of gabapentinoid medication use among US adults with cancer. Investigations on the long-term efficacy of gabapentinoids for complex pain syndromes, and mitigation of risks, is essential to guide informed clinical management and keep patients safe.
KeywordsCancer Supportive care Gabapentin Practice pattern
Concept and design: Fauer, Davis, and Friese. Acquisition, analysis, or interpretation of data: all authors. Drafting of the manuscript: all authors. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: Fauer and Davis. Administrative, technical, or material support: all authors. Supervision: all authors.
Mr. Fauer is supported in part by a Doctoral Scholarship in Cancer Nursing (133507-DSCN-19-048-01-SCN) from the American Cancer Society; the Jonas Nurse Scholars Program; and the Hillman Scholars Program in Nursing Innovation. Research reported in this paper was supported by the National Cancer Institute of the National Institutes of Health under award number P30CA046592 (Friese).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 4.National Cancer Institute. The opioid epidemic and cancer pain management. National Cancer Institute. https://www.cancer.gov/news-events/cancer-currents-blog/2018/opioid-crisis-cancer-pain-paice. Published July 16, 2018. Accessed June 5, 2019.
- 6.Shinde S, Gordon P, Sharma P, Gross J, Davis MP (2015) Use of non-opioid analgesics as adjuvants to opioid analgesia for cancer pain management in an inpatient palliative unit: does this improve pain control and reduce opioid requirements? Support Care Cancer. 23(3):695–703. https://doi.org/10.1007/s00520-014-2415-9 CrossRefPubMedGoogle Scholar
- 8.Agency for Healthcare Research and Quality. Medical expenditure panel survey household component overview. Medical expenditure panel survey. https://meps.ahrq.gov/mepsweb/survey_comp/household.jsp. Published April 22, 2019. Accessed June 5, 2019.
- 11.Yan PZ, Butler PM, Kurowski D, Perloff MD (2013) Beyond neuropathic pain: gabapentin use in cancer pain and perioperative pain. Clin J Pain 1. doi: https://doi.org/10.1097/AJP.0000000000000014
- 18.Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W (2017) Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case–control study. Tsai AC, ed. PLoS Med 14(10):e1002396. https://doi.org/10.1371/journal.pmed.1002396 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Peckham AM, Fairman KA, Sclar DA (2018) All-cause and drug-related medical events associated with overuse of gabapentin and/or opioid medications: a retrospective cohort analysis of a commercially insured US population. Drug Saf. 41(2):213–228. https://doi.org/10.1007/s40264-017-0595-1 CrossRefPubMedGoogle Scholar
- 20.Abou-Khalil B (2008) Levetiracetam in the treatment of epilepsy. Neuropsychiatric Disease and Treatment 507. https://doi.org/10.2147/NDT.S2937